A randomized, controlled study of hyaluronic acid gel for injection combined with botulinum toxin A in the treatment of chin retrusion

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072063

Enrollment

Unknown

Registered

2023-06-01

Start date

2021-12-09

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chin retrusion

Interventions

Combined treatment group:Receive combined treatment with BTX and HA

Monotreatment group:Receive monotreatment with HA

Eligibility

Sex/Gender

All

Age

25 Years to 53 Years

Inclusion criteria

Inclusion criteria: (1) adults aged 18-60 (2) patients defined as Grades 2-3 on Allergan Chin Retrusion Scale

Exclusion criteria

Exclusion criteria: (1) Infection, lesion, inflammation, skin disease around the proposed injection site of the chin (2) Subjects who received chin correction using non-permanent filler within 12 months or permanent implants once (3) Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
Surface-volume coefficient;	—

Secondary

Measure	Time frame
Allergan Chin Retrusion Scale (ACRS);Global Aesthetic Improvement Scale (GAIS);	—

Countries

China

Contacts

Public ContactJin Peisheng

The Affiliated Hospital of Xuzhou Medical University

peishengjin@xzhmu.edu.cn+86 139 1139 1511

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026